The article highlights the findings of a clinical study in Korea which revealed that six cycles of platinum-based first line therapy is not effective against advanced non-small-cell lung cancer (NSCLC). In an editorial accompanying the study, Mark A. Socinski and Thomas E. Stinchcombe of the...
They are often used in combination with other chemotherapy drugs or as part of a larger treatment plan with radiation therapy or surgery. Cancer is a pervasive disease worldwide with millions of people being diagnosed each year. Platinum-based chemotherapy is one of the most commonly used types ...
that glucocorticoids can already by themselves elicit dose-specific responses due to differential expression of glucocorticoid receptor variants, of their cofactors across different cell types16. As with any chemotherapy regimen, vigilance will remain key because therapy resistance may not be present at on...
Carboplatin-based therapy is another alternative, which typically yields less favorable outcomes. Some centers use split-dose cisplatin for treating patients with comorbidities and impaired renal function, broadening cisplatin's spectrum. While eligibility criteria for full-dose cisplatin are ...
We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we ...
A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy in residual colorectal cancer an
Salvage therapies after EGFR TKI therapy and platinum-based chemotherapy provide only limited and transient clinical benefit CNS metastases are common in this population, and therapies to ensure CNS control are needed A phase 1 study of HER3-DXd for advanced NSCLC...
Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents Neoadjuvant therapy, also known as primary, induction, or preoperative therapy, is defined as the first systemic treatment a patient receives after cancer is diagnosed and indicates that subsequent therapies are intended. It was fi...
The proportion of patients with positive HRD status was 64.4%.Such results reveal that, compared to Western population, a higher proportion of Chinese ovarian cancer patients benefit from PARP inhibitor maintenance therapy. Figure 1: Distribution of BRCA1 and BRCA2 gene ...
Although platinum-based chemotherapy can improve pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC), the impact on su